Default Category
-
Imprimis (B)
Casadesus-Masanell, Ramon; Elterman, Karen; Appel, MarcCase HBS-717496-EEntrepreneurshipThis case is a supplement to Imprimis (Case A). It describes the company's decision to enter into the pharmaceutical compounding business in 2013-14. Imprimis purchased a compounded ophthalmological medication called Dropless Therapy, which was injected into patients' eyes post-cataract surgery, with the aim of replacing a complex regimen of prescription eye drops. After a successful launch of the compounded medication, Imprimis ran into complica...Starting at €5.74
-
Imprimis (D)
Casadesus-Masanell, Ramon; Elterman, Karen; Appel, MarcCase HBS-717498-EEntrepreneurshipThis case is a supplement to Imprimis (Case A), Imprimis (Case B), and Imprimis (Case C). It describes Imprimis's 2015 decision to develop a $1 per pill compounded alternative to Daraprim, the branded drug that had recently undergone an extreme price hike, raising its price to $750/pill. Imprimis also created compounded alternatives to several other branded drugs, and made investments to increase its manufacturing capabilities. The company now ha...Starting at €5.74
-
Imprimis (A)
Casadesus-Masanell, Ramon; Elterman, Karen; Appel, MarcCase HBS-717426-EEntrepreneurshipThis case examines the strategic choices and evolving business model of Imprimis Pharmaceuticals from the perspective of CEO Mark Baum. The A case provides a brief history of the company and of the compounding business, outlining the challenges faced by Imprimis in 2013. At the time, Imprimis was in the process of seeking FDA approval for a branded drug called Impracor. This process, already difficult, was further complicated by recent manufactur...Starting at €8.20
-
Imprimis (C)
Casadesus-Masanell, Ramon; Elterman, Karen; Appel, MarcCase HBS-717497-EEntrepreneurshipThis case is a supplement to Imprimis (Case A) and Imprimis (Case B). Set in 2015, it first describes Imprimis's decision to introduce its own line of compounded eye drop medication called LessDrops. The case then examines the moral dilemma faced by CEO Mark Baum, who was struck by the problem of high drug prices in the United States. Recent, drastic price hikes on pharmaceutical drugs, such as those initiated by Turing Pharmaceuticals under CEO ...Starting at €5.74